Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Niraparib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 known ✓ | P09874 | 20/20 | 0.89 |
| ▸ | PARP2 known ✓ | Q9UGN5 | 13/20 | 0.89 |
| ▸ | PARP3 | Q9Y6F1 | 12/20 | 0.89 |
| ▸ | TNKS | O95271 | 1/20 | 0.89 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.89 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.89 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.89 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.89 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.89 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.89 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.89 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.89 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.89 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.89 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.89 |
| ▸ | PARP12 | Q9H0J9 | 1/20 | 0.89 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.89 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.89 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.89 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Niraparib SCHEMBL3659845 | 1.00 | PARP1 (0.89) | PARP1PARP2PARP3TNKSCHRM2 | |
| Niraparib SCHEMBL1421875 | 0.94 | PARP1 (1.00) | PARP1PARP2PARP3TNKSCHRM2 | |
| Niraparib SCHEMBL1422151 | 0.94 | PARP1 (1.00) | PARP1PARP2PARP3TNKSCHRM2 | |
| Niraparib SCHEMBL1421952 | 0.94 | PARP1 (1.00) | PARP1PARP2PARP3TNKSCHRM2 | |
| Niraparib SCHEMBL567839 | 0.93 | PARP1 (0.98) | PARP1PARP2PARP3TNKSCHRM2 | |
| Niraparib SCHEMBL28370623 | 0.93 | PARP1 (0.98) | PARP1PARP2PARP3TNKSCHRM2 | |
| Niraparib SCHEMBL567840 | 0.93 | PARP1 (0.98) | PARP1PARP2PARP3TNKSCHRM2 | |
| Niraparib SCHEMBL1422061 | 0.93 | PARP1 (0.98) | PARP1PARP2PARP3TNKSCHRM2 | |
| Niraparib SCHEMBL28129248 | 0.92 | PARP1 (0.77) | PARP1PARP2PARP3TNKSCHRM2 | |
| Niraparib SCHEMBL3740349 | 0.92 | PARP1 (0.91) | PARP1PARP2PARP3TNKSCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2240466-B1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 2-{4-[(3S)-PIPERIDIN-3- YL]PHENYL} -2H-INDAZOLE-7-CARBOXAMIDE | MERCK SHARP & DOHME (GB) | 2015-07-29 | — | — | EP | claimed |
| US-20100286203-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 2--2H-INDAZOLE-7-CARBOXAMIDE | MERCK SHARP & DOHME LLC | 2010-11-11 | — | — | US | claimed |
| EP-2240466-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 2-{4-[(3S)-PIPERIDIN-3- YL]PHENYL} -2H-INDAZOLE-7-CARBOXAMIDE | Merck Sharp & Dohme Limited (GB) | 2010-10-20 | — | — | EP | claimed |
| WO-2009087381-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 2-{4-[(3S)-PIPERIDIN-3- YL]PHENYL} -2H-INDAZOLE-7-CARBOXAMIDE | MERCK SHARP & DOHME LTD (GB) | 2009-07-16 | — | — | WO | claimed |
| EP-2240466-B1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 2-{4-[(3S)-PIPERIDIN-3- YL]PHENYL} -2H-INDAZOLE-7-CARBOXAMIDE | MERCK SHARP & DOHME (GB) | 2015-07-29 | — | — | EP | disclosed |
| US-8436185-B2 | Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide | MERCK SHARP & DOHME CORP. (US) | 2013-05-07 | — | — | US | disclosed |
| US-20100286203-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 2--2H-INDAZOLE-7-CARBOXAMIDE | MERCK SHARP & DOHME LLC | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286203-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF 2--2H-INDAZOLE-7-CARBOXAMIDE | PARP1, PARP12, PARP15 | PARP1 1/4885PARP2 6/4885PARP3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.